Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Cardiol Cases ; 29(3): 101-103, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38481637

RESUMO

Papillary muscle rupture is usually caused by myocardial infarction although rare cases of non-ischemic etiology have also been described. Among these, infective endocarditis represents an important cause. Herein, we report a case due to Streptococcus agalactiae involving the posteromedial papillary muscle. Learning objective: Non-ischemic papillary muscle rupture should be suspected when there is no evidence of atherosclerotic coronary artery disease. In the febrile patient, infective endocarditis should be considered in the differential diagnosis.

2.
Am J Clin Pathol ; 160(1): 35-40, 2023 07 05.
Artigo em Inglês | MEDLINE | ID: mdl-36897217

RESUMO

OBJECTIVES: To determine the prognostic significance of the maximum allowable percentage of Gleason pattern 4 (GP4) at prostate biopsy compared with adverse pathology observed at radical prostatectomy (RP) to expand active surveillance eligibility among a cohort with intermediate risk of prostate cancer. METHODS: A retrospective study of patients with grade group (GG) 1 or 2 prostate cancer on prostate biopsy with subsequent RP was performed at our institution. A Fisher exact test was used to understand the relationship among GP4 subgroups (0%, ≤5%, 6%-10%, and 11%-49%) assigned at biopsy and adverse pathologic findings at RP. Additional analyses comparing the GP4 ≤5% cohort's prebiopsy prostate-specific antigen (PSA) level and GP4 length with adverse pathology at RP were also performed. RESULTS: No statistically significant difference in adverse pathology at RP was observed between the active surveillance-eligible control (GP4 0%) and the GP4 ≤5% subgroup. In total, 68.9% of the GP4 ≤5% cohort showed favorable pathologic outcomes. A separate analysis of the GP4 ≤5% subgroup revealed that neither prebiopsy serum PSA levels nor GP4 length showed statistical correlation with adverse pathology at RP. CONCLUSIONS: Active surveillance may be a reasonable option for management of patients in the GP4 ≤5% group until long-term follow-up data become available.


Assuntos
Próstata , Neoplasias da Próstata , Masculino , Humanos , Próstata/cirurgia , Próstata/patologia , Antígeno Prostático Específico , Estudos Retrospectivos , Conduta Expectante , Biópsia , Prostatectomia , Neoplasias da Próstata/patologia , Gradação de Tumores
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA